The health-care sector fell as earnings came in generally weak. Eli Lilly posted a decline in quarterly profit despite higher drug sales as higher research-and-development costs and a currency devaluation in Venezuela took their toll. Sarepta Therapeutics plunged after an advisory panel to the Food and Drug Administration voted not to recommend approval of its drug for Duchenne muscular dystrophy, which had excited hopes among investors. (rob.curran@dowjones.com)

(END) Dow Jones Newswires

April 26, 2016 16:26 ET (20:26 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Eli Lilly Charts.